Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| AstraZeneca to acquire Amolyt | 14 Mar 2024 |
| Director/PDMR Shareholding | 12 Mar 2024 |
| Notice of AGM | 7 Mar 2024 |
| Director/PDMR Shareholding | 6 Mar 2024 |
| Director/PDMR Shareholding | 6 Mar 2024 |
| EMA validates Dato-DXd MAAs for NSQ NSCLC and BC | 4 Mar 2024 |
| Total Voting Rights | 1 Mar 2024 |
| Voydeya recommended for EU approval | 26 Feb 2024 |
| AstraZeneca prices a $5bn bond offering | 22 Feb 2024 |
| Director/PDMR Shareholding | 22 Feb 2024 |
| Acquisition of Gracell completed | 22 Feb 2024 |
| Filing of Form 20-F with SEC | 21 Feb 2024 |